

# Exhibit A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	10/593,217
Filing Date	September 15, 2006
First Named Inventor	KING, et al.
Art Unit	Not Yet Known 1623
Examiner Name	Not Yet Known Ganapathy Krishnan
Attorney Docket Number	891-A-PCT-US

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/G.K./	1	US- 4,175,200	11-20-1979	Hunter, et al.		
	2	US- 4,385,055	05-24-1983	Klayman, et al.		
	3	US- 4,447,427	05-08-1984	Klayman, et al.		
	4	US- 4,684,747	08-04-1987	Satorelli, et al.		
	5	US- 4,696,938	09-29-1987	Satorelli, et al.		
	6	US- 4,849,563	07-18-1989	Satorelli, et al.		
	7	US- 5,101,072	03-31-1992	Satorelli, et al.		
	8	US- 5,214,068	05-25-1993	Satorelli, et al.		
	9	US- 5,256,820	10-26-1993	Satorelli, et al.		
	10	US- 5,637,619	06-10-1997	Satorelli, et al.		
	11	US- 5,767,134	06-16-1998	Li, et al.		
	12	US- 6,040,338	03-21-2000	Satorelli, et al.		
	13	US- 6,696,487	02-24-2004	Gerusz, et al.		
/G.K./	14	US- 6,855,695	02-15-2005	Xu, et al.		
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/G.K./	15	WO/2002/030424	04-18-2002	Doyle, et al.		

Examiner Signature	/Ganapathy Krishnan/	Date Considered	05/08/2008
--------------------	----------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Application Number</b>	10/593,217
		<b>Filing Date</b>	September 15, 2006
		<b>First Named Inventor</b>	KING, et al.
		<b>Art Unit</b>	Not Yet Known
		<b>Examiner Name</b>	Not Yet Known
<b>Sheet</b>	2	<b>of</b>	3
		<b>Attorney Docket Number</b>	891-A-PCT-US

<b>OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/G.K./	16	Baumann RP, et al., 2004, "1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity." Cancer Chemother Pharmacol. 53(4):288-295		
	17	Burchenal, et al., 1988, "Cancer: the Outlaw Cell," ed. Richard E Lafond, American Chemical Society: 204-205		
	18	Gura, et al., 1997, "Systems for identifying new drugs are often faulty." Science: 278(5340):1041-2		
	19	Lee, et al., 2002, "Toxicological evaluation of 1,2 bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M), novel alkylating Agent with Potential Antitumor Activity, with Intravenous Administration In Rats and Dogs", International Journal of Toxicology. Vol. 23: 23-39		
	20	Hrubiec, et al., 1986, "Synthesis and evaluation of 1-(arylsulfonyl)-2-[(methoxycarbonyl)sulfonyl]-1-methylhydrazines ++ as antineoplastic agents." J Med Chem. 29(9):1777-9		
	21	Hrubiec, et al., 1986, "Synthesis and evaluation of 2-substituted 1-methyl-1-(4-tolylsulfonyl)hydrazines as antineoplastic agents," J Med Chem. 29(7):1299-301		
	22	Murren, et al., 2005, "A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer", Investigational New Drugs. Vol 23: 123-135		
	23	Mao, et al., 2002, "Pharmacokinetics, Mass Balance, and Tissue Distribution of a Novel DNA Alkylating Agent, VNP40101M, in Rats", AAPS PharmSci: 4(4)24		
	24	Penketh, et al., 1994, "Studies on the mechanism of decomposition and structural factors affecting the aqueous stability of 1,2-bis(sulfonyl)-1-alkylhydrazines," J Med Chem 37: 2912-2917		
/G.K./	25	Penketh, et al., 2000, "Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas", Biochem Pharmacol 59:283-91		

<b>Examiner Signature</b>	/Ganapathy Krishnan/	<b>Date Considered</b>	05/08/2008
---------------------------	----------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

Application Number	10/593,217
Filing Date	September 15, 2006
First Named Inventor	KING, et al.
Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	891-A-PCT-US

**OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/G.K./	26	Pratviel, et al., 1989, "Cytotoxic and DNA-damaging Effects of 1,2-bis(sulfonyl)hydrazines on Human Cells of the Mer+ and Mer- phenotype", Cancer Biochem Biophys 10:365-75 (abstract only)	
	27	Shyam, et al., 1985, "Synthesis and evaluation of N,N-bis(arylsulfonyl)hydrazines as antineoplastic agents" J Med Chem 28:525-7	
	28	Shyam, et al., 1986, "1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity", J Med Chem 29:1323-5	
	29	Shyam, et al., 1987, "1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity", J Med Chem 30:2157-61	
	30	Shyam, et al., 1990, "Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents", J Med Chem. 33(8):2259-64	
	31	Shyam, et al., 1993, "Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazines as antineoplastic agents", J Med Chem 36:3496-502	
	32	Shyam, et al., 1996, Antitumor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)- hydrazines", J Med Chem 39:796-801	
	33	Giles, et al., 2004, "A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia.", Clinical Cancer Research, Vol. 10, Pages 2908-2917	
	34	Ishiguro, et al., 2005, "Role of O-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine", Mol Cancer Ther, Vol. 4 (11), Pages 1755-1763	
/G.K./	35	Rice, et al., 2005, "Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU.", Biochemical Pharmacology, Vol. 69, Pages 1463-1472	

Examiner  
Signature

/Ganapathy Krishnan/

Date  
Considered

05/08/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.